Dizon Romeo R

CFO Romeo R. Dizon buys 1,110 shares of IRIX at $1.26; small position addition to 121.0K holdings amid unprofitable financials.

CFO Romeo R. Dizon purchased 1,110 shares at $1.26 on 2026-03-06, a modest addition (+0.9%) to his 121.0K-share position. The company is unprofitable (net income $-1.6M) with annual revenue declining -6.2%, and the stock has fallen -18.0% from its 52-week high and -12.3% over the past 30 days. The insider's cross-ticker track record shows strong average returns (90d +50.0% with 100% win rate across 20 prior buys), but his same-ticker history at IRIX shows 5 prior buys (4 with outcomes not yet measurable, 1 with flat 30d return) with no well-timed entries at the 90-day mark. The small, incremental nature of this purchase and recent stock weakness contrast with the underlying operational headwinds and lack of measurable positive outcomes from his prior IRIX trades.

CFO Romeo R Dizon buys 2,200 IRIX shares across 2 transactions for blended avg $1.34; 5th consecutive buy in 10 days

Romeo R Dizon, Chief Financial Officer, executed 2 separate purchases totaling 2,200 shares (2.2K shares) for $2,942.00, raising his holdings from 117,690 to 119,890 shares. This filing is the fifth consecutive insider buy at IRIX within a 10-day window (purchases on 2026-01-28, 2026-01-29, 2026-02-03, 2026-02-10, and 2026-02-12 precede this 2026-02-17 transaction), indicating sustained accumulation near current price levels. The company faces fundamental headwinds: latest quarterly revenue of $12,484,000.00 paired with a net loss of $-1,573,000.00, alongside annual revenue decline of -6.2%, making this buying pattern noteworthy against an unprofitable backdrop. Current price of $1.32 sits 15.4% below the 52-week high of $1.56, yet the insider's transactions at $1.37 and $1.31 demonstrate purchases occurring as the stock declined 6.4% over the prior 30 days—a pattern warrant deep analysis on whether the CFO's sustained accumulation reflects conviction despite deteriorating fundamentals or reflects planned purchasing discipline unrelated to operational trajectory.

CFO Dizon Romeo R bought 1,500 shares of IRIX at $1.43 on 2026-02-12; stock now at $1.38, off 52-week high

CFO Dizon Romeo R purchased 1,500 shares at $1.43 on 2026-02-12, bringing his holdings to 117,690 shares total, within days of four prior buys at the same ticker (2026-01-27 through 2026-02-10). The stock currently trades at $1.38, -14.3% from its 52-week high of $1.61, while the company reported negative net income of $-1,573,000 and declining annual revenue (-6.2% year-over-year). These repeated purchases into an unprofitable company with contracting revenues and depressed valuation merit scrutiny regarding the CFO's assessment of intrinsic value versus current market pricing, though the small transaction size ($2,145.00) and recent timing of all five same-ticker trades remain measurable only at longer horizons.

CFO Dizon Romeo R buys 1,000 shares of IRIX at $1.46; company unprofitable with -6.2% annual revenue decline

CFO Dizon Romeo R purchased 1,000 shares at $1.46 on 2026-02-10, bringing his holdings to 116.2K shares, as part of a pattern of 5 consecutive buys at IRIX within two weeks (2026-01-26 through 2026-02-03). The transaction occurs against a backdrop of deteriorating fundamentals: the company reported Revenue $12.5M with Net income $-1.6M in the latest quarter, annual revenue growth of -6.2%, and remains unprofitable on a full-year basis. The stock is trading at $1.43, down 12.8% from its 52-week high of $1.64, though it has gained 24.4% over the past 30 days and 49.9% over 90 days. While the CFO's cross-ticker track record shows 20 prior buys with an average 30-day return of +10.8%, his five recent purchases at IRIX have outcomes not yet measurable. The cluster of rapid purchases by the CFO during a revenue-decline period warrants attention to whether these acquisitions reflect conviction in a recovery or other undisclosed considerations.

CFO Romeo R Dizon bought 2,500 shares of IRIX at $1.38 on 2026-02-03; fifth consecutive buy in four days amid unprofitable operations.

Dizon Romeo R, Chief Financial Officer, purchased 2,500 shares of IRIDEX CORP at $1.38 on 2026-02-03, bringing his holdings to 115,190 shares. This transaction is part of an unusual pattern: five separate buys at IRIX occurred between 2026-01-23 and 2026-01-29, all outcomes unyet measurable. The company faces material operational headwinds—it is unprofitable with net income of $-1,573,000.00 over its most recent full fiscal year and annual revenue contracted -6.2%. Current valuation is modest at $24,409,773.02 market cap. The insider's cross-ticker track record shows a +9.9% average 30-day return on 20 prior buys, but no prior trades at IRIX reached the 90-day measurement window to evaluate outcomes at this specific ticker. The 30-day price action has been positive (+21.4%), yet the stock remains -13.4% from its 52-week high, providing limited visibility into whether this accumulation pattern reflects fundamentally informed conviction or simply opportunistic purchasing at a depressed price point.

CFO Dizon Romeo R bought 1,101 shares of IRIX at $1.44 on 2026-01-29 as part of a buying streak—five consecutive days of purchases.

Dizon Romeo R, Chief Financial Officer of IRIDEX CORP, purchased 1,101 shares at $1.44 on 2026-01-29, bringing his holdings to 112,690 shares. This transaction is the latest in a rapid sequence: the insider executed five separate buys at IRIX over five consecutive trading days (2026-01-21 through 2026-01-29), with no measurable outcomes yet from any of these trades. The price action context is mixed—the stock is currently at $1.49 (up 29.6% over 30 days and 41.9% over 90 days) but sits 10.2% below its 52-week high of $1.66. Fundamentally, the company faces headwinds: most recent quarterly revenue of $12.5M is declining on an annual basis (-6.2%), the company posted a net loss of $-1.6M in the latest quarter, and the full fiscal year was unprofitable. The pattern of consecutive daily purchases by the CFO at a micro-cap company ($25.6M market cap) during a period of operational losses and revenue contraction merits investor attention, though the recency of these trades and the rapid price recovery leave no basis yet to assess their timing quality.

CFO Romeo R Dizon bought 1,300 shares of IRIX at $1.46 on 2026-01-28, part of a 5-trade buying streak in 4 days

Dizon purchased 1,300 shares at $1.46 on 2026-01-28, adding to a pattern of 4 other open-market buys at the same ticker within a 7-day window (2026-01-21 through 2026-01-27). The cumulative effect raises his holdings from 110,289 to 111,589 shares (+1.2%). IRIX trades at $1.48 currently, within its 52-week range of $0.79–$1.66, and has appreciated 26.5% over 30 days and 39.6% over 90 days. However, Dizon's cross-ticker track record shows 0 of 20 prior buys were well-timed on a 90-day basis (win rate 0.00%, average 90d return −29.2%), and his same-ticker outcomes at IRIX are not yet measurable. The company is unprofitable (net income −$1.6M in the latest quarter, annual revenue declined 6.2% year-over-year), creating a divergence between price strength and fundamental weakness that warrants attention.

CFO Dizon Romeo R bought 3.4K shares of IRIX at $1.48 on 2026-01-27, adding to five consecutive purchases within one week.

Dizon Romeo R, Chief Financial Officer of IRIDEX CORP, purchased 3,385 shares at $1.48 on 2026-01-27, bringing holdings from 106,904 to 110,289 shares. This transaction is part of an unusual pattern: the same insider executed five consecutive buy orders at IRIX between 2026-01-20 and 2026-01-27, all outcomes remain unmeasured (within 30 and 90 days). The company's fundamentals are strained—annual revenue declined 6.2% to $12.5M in the latest quarter, and the firm posted a $-1.6M net loss, remaining unprofitable over the full fiscal year. While the stock has rallied +24.4% in 30 days and +48.5% in 90 days from recent lows, the CFO's cross-ticker track record shows a 0.00% win rate on 90-day returns across 20 prior buys (average 90d return: -28.9%), providing limited evidence of timing acumen at other securities. Investors should monitor whether the rapid accumulation reflects management's view of turnaround potential or responds to external catalysts not yet apparent in public filings.

CFO Romeo Dizon buys 1,243 shares of IRIX at $1.52 on 2026-01-23; stock at -7.7% from 52-week high, amid unprofitable fundamentals.

Dizon Romeo R (CFO) purchased 1,243 shares at $1.52 on 2026-01-26, adding to his 105,661-share base for a modest 1.2% increase in holdings. This is the fifth consecutive open-market buy at IRIX over a six-day span (2026-01-16 through 2026-01-26), suggesting incremental accumulation rather than a single conviction trade. However, context tempers significance: the company is unprofitable (net income $-1.6M in the latest quarter, annual revenue declining -6.2%), and the CFO's cross-ticker buy track record shows 0 out of 20 prior buys with a positive 90-day outcome (90d win rate 0.00%, avg 90d return -29.2%). None of his five recent IRIX trades have measurable outcomes yet. The stock has risen +26.8% over 30 days and +54.5% over 90 days from prior lows, now trading -7.7% from its 52-week high, leaving limited room for near-term upside on recent momentum.

IRIX CFO buys 5,221 shares at $1.48 amid unprofitable operations and -6.2% annual revenue decline

Dizon Romeo R, the CFO, purchased 5,221 shares at $1.48 on 2026-01-23, bringing his holdings to 105,661 shares (a 5.2% increase). This is the fifth distinct buy transaction at IRIX within a week, clustering between 2026-01-16 and 2026-01-23. Notably, the company reported revenue of $12,484,000 with net income of $-1,573,000 (unprofitable), and annual revenue growth was -6.2%, indicating financial stress. The stock's current price of $1.52 is 10.1% below its 52-week high of $1.69, though recent momentum is positive (+33.3% over 30 days, +38.8% over 90 days). However, the CFO's cross-ticker track record shows a 0.00% win rate on buys over 90 days (avg 90d return -29.5% across 20 prior open-market purchases across all tickers), suggesting a consistent pattern of poorly-timed acquisitions. The convergence of deteriorating fundamentals, an extended buying spree by the CFO despite his track record, and the stock's recovery from recent lows warrants examination of whether this represents conviction or a predetermined acquisition plan.